Cantourage Group SE Logo

Cantourage Group SE

A European platform producing and distributing medical cannabis products to pharmacies.

HIGH | XMIL

Overview

Corporate Details

ISIN(s):
DE000A3DSV01
LEI:
3912003NCTLO6YHA9V48
Country:
Germany
Address:
Feurigstraße 54, 10827 Berlin
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cantourage Group SE is a leading European medical cannabis company that produces and distributes cannabis-based medicinal preparations. Founded in 2019, the company operates a 'fast-track' platform model, sourcing cannabis flowers and raw materials from a global network of cultivation partners. It manages the import and processing of these materials into EU-compliant pharmaceutical products at its European manufacturing hubs, handling all regulatory complexities. The product portfolio includes dried flowers, extracts, dronabinol, and pharma-grade cannabidiol, which are distributed to pharmacies through wholesalers. Cantourage also facilitates patient access to medical cannabis therapies through its telemedicine platform, Telecan.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-04 12:00
Regulatory Filings
Cantourage strengthens market presence in Poland with flower variety Gelato 33
English 10.7 KB
2025-10-30 10:08
Earnings Release
Q3 2025: Cantourage delivers strong operating performance in a challenging regu…
English 9.7 KB
2025-10-15 15:49
Regulatory Filings
Cabinet decision on the Medical Cannabis Act meets broad criticism / Cantourage…
English 13.0 KB
2025-10-08 13:01
Regulatory Filings
Cantourage is responding to potential developments resulting from new legal reg…
English 8.3 KB
2025-10-01 09:47
Board/Management Information
Cantourage Strengthens Capital Markets Presence: New Head of Investor Relations…
English 7.4 KB
2025-10-01 09:39
Director's Dealing
Cantourage Group SE: Philip Schetter, Acquisition of 188,639 Shares as Part of …
English 6.1 KB
2025-09-04 09:00
Business and Financial Review
Cantourage Group SE Update
German 12.5 KB
2025-07-09 18:42
Board/Management Information
Ad-hoc-Mitteilung nach Art. 17 Marktmissbrauchsverordnung - Cantourage Group SE…
German 4.6 KB
2025-05-20 07:51
Earnings Release
Cantourage achieves strong and profitable growth in the first quarter of 2025
English 7.4 KB
2025-05-15 07:07
Earnings Release
Cantourage achieves another record revenue: EUR 11.1 million in April 2025
English 6.6 KB
2025-04-11 09:03
Earnings Release
Ad-hoc: Record quarter for Cantourage-Group: EUR 25.6 million revenue in Q1 202…
English 6.8 KB
2025-04-10 08:52
Earnings Release
Record quarter for Cantourage-Group: EUR 25.6 million revenue in Q1 for the fi…
English 9.0 KB
2025-03-11 08:31
Earnings Release
Cantourage Group SE: Starker Jahresendspurt und anhaltendes Wachstum in 2025
German 7.6 KB
2025-03-10 08:31
Earnings Release
Cantourage Group SE: Starker Jahresendspurt und anhaltendes Wachstum in 2025
German 7.6 KB
2025-01-16 07:30
Earnings Release
Legalization of cannabis brings strong growth: Cantourage Group SE increases it…
English 10.0 KB

Automate Your Workflow. Get a real-time feed of all Cantourage Group SE filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cantourage Group SE

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cantourage Group SE via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-01-02 Think.Health Projekt M GmbH & Co. KG Close relation Sell None 72,010.80 EUR
2024-11-25 PiFriva Verwaltungs- und Beteiligungs-GmbH Close relation Sell None 200,000.00 EUR
2024-09-13 PiFriva Verwaltungs- und Beteiligungs-GmbH Close relation Sell None 105,000.00 EUR
2024-07-18 PiFriva Verwaltungs- und Beteiligungs-GmbH Close relation Sell None 140,000.00 EUR
2024-06-06 HOFY4 GmbH Close relation Sell None 345,000.00 EUR
2024-05-27 HOFY4 GmbH Close relation Sell None 7,400.00 EUR
2024-05-17 HOFY4 GmbH Close relation Sell None 140,000.00 EUR
2024-05-17 HOFY4 GmbH Close relation Sell None 1,080.00 EUR
2024-02-21 HOFY4 GmbH Close relation Sell None 63,205.88 EUR
2024-02-14 Think.Health Projekt M GmbH & Co. KG Close relation Sell None 82,415.57 EUR

Peer Companies

Klaria Pharma Holding AB Logo
Develops oral films for non-invasive drug delivery as an alternative to injections and sprays.
Sweden
KLAR
Klotho Neurosciences, Inc. Logo
Advancing gene and cell therapies for neurodegenerative disorders, cancer, and chronic diseases.
United States of America
KLTO
KOA SHOJI HOLDINGS CO.,LTD. Logo
Imports APIs and manufactures generic drugs for Japan's pharmaceutical industry.
Japan
9273
KOBAYASHI PHARMACEUTICAL  CO.,LTD. Logo
Manufactures OTC pharma, personal care, and household goods for niche consumer markets.
Japan
4967
Kodiak Sciences Inc. Logo
Developing durable biologics to treat high-prevalence retinal diseases and prevent blindness.
United States of America
KOD
Kohjin Bio Co., Ltd. Logo
A CDMO providing culture media & bioservices for cell therapy, research, and diagnostics.
Japan
177A
KOLON LIFE SCIENCE Inc. Logo
Develops gene therapies and manufactures APIs, providing global CDMO/CMO services.
South Korea
102940
Kolon TissueGene, Inc. Logo
Developing cell and gene therapies for orthopedic and degenerative disorders.
United States of America
950160
Develops animal health products and novel drugs for human cancer and autoimmune diseases.
South Korea
041960
KOREA ARLICO PHARM CO.,LTD. Logo
Manufactures generic drugs and provides CDMO services to a global market.
South Korea
260660

Talk to a Data Expert

Have a question? We'll get back to you promptly.